Propanc Biopharma Common Stock Net Income
| PPCB Stock | USD 0.23 0.05 17.86% |
As of the 30th of January, Propanc Biopharma, holds the Coefficient Of Variation of (331.29), variance of 55.66, and Risk Adjusted Performance of (0.21). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Propanc Biopharma,, as well as the relationship between them.
Propanc Biopharma,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Propanc Biopharma,'s valuation are provided below:Propanc Biopharma Common does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Propanc |
Propanc Biopharma, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Propanc Biopharma,'s pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Propanc Biopharma,.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Propanc Biopharma, on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Propanc Biopharma Common or generate 0.0% return on investment in Propanc Biopharma, over 90 days. Propanc Biopharma, is related to or competes with Telescope Innovations, ImmunoCellular Therapeutics, Cell Source, and Hookipa Pharma. Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, ... More
Propanc Biopharma, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Propanc Biopharma,'s pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Propanc Biopharma Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.31) | |||
| Maximum Drawdown | 27.99 | |||
| Value At Risk | (12.62) | |||
| Potential Upside | 7.89 |
Propanc Biopharma, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Propanc Biopharma,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Propanc Biopharma,'s standard deviation. In reality, there are many statistical measures that can use Propanc Biopharma, historical prices to predict the future Propanc Biopharma,'s volatility.| Risk Adjusted Performance | (0.21) | |||
| Jensen Alpha | (2.23) | |||
| Total Risk Alpha | (2.79) | |||
| Treynor Ratio | 4.23 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Propanc Biopharma,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Propanc Biopharma, January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.21) | |||
| Market Risk Adjusted Performance | 4.24 | |||
| Mean Deviation | 4.91 | |||
| Coefficient Of Variation | (331.29) | |||
| Standard Deviation | 7.46 | |||
| Variance | 55.66 | |||
| Information Ratio | (0.31) | |||
| Jensen Alpha | (2.23) | |||
| Total Risk Alpha | (2.79) | |||
| Treynor Ratio | 4.23 | |||
| Maximum Drawdown | 27.99 | |||
| Value At Risk | (12.62) | |||
| Potential Upside | 7.89 | |||
| Skewness | 0.5773 | |||
| Kurtosis | 6.27 |
Propanc Biopharma Common Backtested Returns
Propanc Biopharma Common maintains Sharpe Ratio (i.e., Efficiency) of -0.29, which implies the firm had a -0.29 % return per unit of risk over the last 3 months. Propanc Biopharma Common exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Propanc Biopharma,'s Variance of 55.66, coefficient of variation of (331.29), and Risk Adjusted Performance of (0.21) to confirm the risk estimate we provide. The company holds a Beta of -0.53, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Propanc Biopharma, are expected to decrease at a much lower rate. During the bear market, Propanc Biopharma, is likely to outperform the market. At this point, Propanc Biopharma Common has a negative expected return of -2.26%. Please make sure to check Propanc Biopharma,'s potential upside and the relationship between the accumulation distribution and period momentum indicator , to decide if Propanc Biopharma Common performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.66 |
Good predictability
Propanc Biopharma Common has good predictability. Overlapping area represents the amount of predictability between Propanc Biopharma, time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Propanc Biopharma Common price movement. The serial correlation of 0.66 indicates that around 66.0% of current Propanc Biopharma, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.66 | |
| Spearman Rank Test | 0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Propanc Biopharma Common reported net income of (2.66 Million). This is 100.78% lower than that of the Biotechnology sector and 103.79% lower than that of the Health Care industry. The net income for all United States stocks is 100.47% higher than that of the company.
Propanc Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Propanc Biopharma,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Propanc Biopharma, could also be used in its relative valuation, which is a method of valuing Propanc Biopharma, by comparing valuation metrics of similar companies.Propanc Biopharma is currently under evaluation in net income category among its peers.
Propanc Fundamentals
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Shares Owned By Insiders | 1.60 % | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Net Income | (2.66 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.44 M) | |||
| Earnings Per Share | (0.09) X | |||
| Target Price | 1.52 | |||
| Beta | 1.42 | |||
| Market Capitalization | 705.56 K | |||
| Total Asset | 81.65 K | |||
| Z Score | -85.8 | |||
| Net Asset | 81.65 K |
About Propanc Biopharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Propanc Biopharma Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Propanc Biopharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Propanc Biopharma Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma, financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma, security.